Trial Profile
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Efineptakin alfa (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2024 Planned End Date changed from 31 Jan 2030 to 31 Jan 2032.
- 11 Jan 2024 Planned primary completion date changed from 31 Jan 2030 to 31 Jan 2032.
- 19 Jan 2023 Planned End Date changed from 31 Jul 2028 to 31 Jan 2030.